


Mezigdomide

Chemical Properties

CAS No. :	2259648-80-9
Formula:	C32H30FN5O4
Molecular Weight:	567.61
Storage:	Keep away from direct sunlight Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Mezigdomide (CC-92480) is a potent, novel, selective and active cereblon E3 ubiquitin ligase modulator (CELMoD) that acts as a molecular glue. Mezigdomide has anti-myeloma activity. [1]
Targets(IC50)	Apoptosis,E1/E2/E3 Enzyme,Molecular Glues
In vitro	Mezigdomide (CC-92480)-induced loss of Aiolos and Ikaros in PBMC cultures resulted in T cell activation and increased IL-2 and IFN- γ production; Mezigdomide (CC-92480) induced apoptosis as a single agent and exhibited significant synergy with NSC 34521; Mezigdomide (CC-92480) was effective against CC-4047, CC-5013, and CC-220 resistant cell lines. [2]
In vivo	Mezigdomide (1 mg/kg) reduced tumor volume by 75% when administered orally to tumor-bearing mice for 21 days[2].

Solubility Information

Solubility	DMSO: 5 mg/mL (8.81 mM),Sonication and heating to 60°C are recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7618 mL	8.8089 mL	17.6177 mL
5 mM	0.3524 mL	1.7618 mL	3.5235 mL
10 mM	0.1762 mL	0.8809 mL	1.7618 mL
50 mM	0.0352 mL	0.1762 mL	0.3524 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Hartley-Brown MA, et al. Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma. *Cancers (Basel)*. 2024 Mar 15;16(6):1166.

Nooka AK, et al. Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. *Cancer J*. 2019 Jan/Feb;25(1):19-31.

Hansen JD, et al. Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma. *J Med Chem*. 2020 Jul 9;63(13):6648-6676.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481